Human IFNAR Antibody - Anifrolumab Biosimilar

Binding of anti-IFNAR-mAb

Anti-human IFNAR1 - Anifrolumab biosimilar - CAS #1326232-46-5

Anti-hIFNAR-hIgG1-FES is the biosimilar antibody of Anifrolumab, a human type I interferon (IFN) receptor subunit 1 (IFNAR1) antibody that inhibits type I IFN signaling. This monoclonal antibody (mAb) is FDA-approved is approved for the treatment of systemic lupus erythematosus (SLE).

 More details

Anti-hIFNAR-hIgG1-FES comprises the variable region of Anifrolumab and the effectorless IgG1 constant region of Anifrolumab harboring a triple mutation L234F/L235E/P331S (FES). 

This antibody can be used together with HEK-Blue™ IFN-α/β cells for screening and neutralization assays to inhibit IFN-α/β signaling induced by recombinant human IFN-α or IFN-β (see figure).

Key features

• Each lot is functionally tested and validated
• The complete sequence of the antibody construct has been verified
• The absence of endotoxins is determined by the EndotoxDetect assay

If you are interested in the corresponding isotype control Anti-β-Gal-hIgG1-FES mAb, please contact us. 

InvivoGen’s products are for research use only, and not for clinical or veterinary use.

Figures

Dose-dependent inhibition of HEK-Blue™ IFN-α/β cells response using Anti-hIFNAR-hIgG1-FES. HEK-Blue™ IFN-a/b cells were incubated with increasing concentrations of Anti-hIFNAR-hIgG1-FES (0.1 ng/ml - 10 µg/ml) for 1 h before the addition of recombinant human IFN-α (100 pg/ml). After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are shown in percentage of activity (mean ± SEM).

Specifications

Application: Neutralization assay, ELISA, Effector function analysis

Isotype:  Human IgG1, kappa featuring triple mutation L234F/L235E/P331S

Recommended isotype control: Contact us

Target: Human IFNAR1

Species reactivity: Human

Clone: Anifrolumab

Cas number: 1326232-46-5

Sterility: 0.2 µm filtration

Source: CHO cells 

Production: Animal-free

Purification: Protein A

Molecular weight: 147.2 kDa

Physical form: Lyophilized

Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative: Azide-free

Reconstitution buffer: Sterile water (not provided)

Purity: ≥ 95 %

Quality control: Each lot is functionally tested and validated

Contents

Anti-hIFNAR-hIgG1-FES purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

• hifnar-mab16: 100 µg
• hifnar-mab16-03: 3 x 100 µg

Tags: buy Anifolumab (anti-IFNAR) | Anifolumab (anti-IFNAR) supplier | purchase Anifolumab (anti-IFNAR) | Anifolumab (anti-IFNAR) cost | Anifolumab (anti-IFNAR) manufacturer | order Anifolumab (anti-IFNAR) | Anifolumab (anti-IFNAR) distributor

Details

Anifrolumab background

Anifrolumab is a fully human mAb designed to target the type I interferon (IFN) receptor subunit 1 (IFNAR1) and to block the type I IFN signaling. Anifrolumab features a triple mutation L234F/L235E/P331S in the heavy chain to reduce engagement with the cell surface Fc gamma receptor (FcγR) and potential Fc-mediated effector function, such as antibody-dependent cell-mediated cytotoxicity (ADCC) [1-2]. According to the FDA, it is a first-in-class medication highlighting its innovative and unique mechanism of action [3]. It has been approved as an add-on therapy for moderately to severely active systemic lupus erythematosus (SLE) [3].

References:

1. Plüß M, et al., 2022. Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab-A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach. J Clin Med. 11(12):3449.
2. Riggs JM, et al., 2018. Characterization of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 5(1):e000261.
3. U.S. Food and Drug Administration (FDA) (Report). 2022. Advancing Health Through Innovation: New Drug Therapy Approvals 2021.